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Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as
sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in
diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic
transgenic GluCreERT2;ROSA26-eYFP and Ins1Cre/+;Rosa26-eYFP mouse models have
been used to study effects of sustained NPYR1 activation on islet cell composition and
alpha- and beta-cell lineage transitioning. STZ induced a particularly severe form of
diabetes in Ins1Cre/+;Rosa26-eYFP mice, but twice-daily administration (25 nmol/kg) of
SL-PYY(1-36) for 11 days consistently improved metabolic status. Blood glucose was
decreased (p < 0.05 - p < 0.001) and both fasted plasma and pancreatic insulin
significantly increased by SL-PYY(1-36). In both GluCreERT2;ROSA26-eYFP and Ins1Cre/+;
Rosa26-eYFP mice, STZ provoked characteristic losses (p < 0.05 - p < 0.001) of islet
numbers, beta-cell and pancreatic islet areas together with increases in area and central
islet location of alpha-cells. With exception of alpha-cell area, these morphological
changes were fully, or partially, returned to non-diabetic control levels by SL-PYY(1-36).
Interestingly, STZ apparently triggered decreased (p < 0.001) alpha- to beta-cell transition
in GluCreERT2;ROSA26-eYFP mice, together with increased loss of beta-cell identity in
Ins1Cre/+;Rosa26-eYFP mice, but both effects were significantly (p < 0.001) reversed by
SL-PYY(1-36). SL-PYY(1-36) also apparently reduced (p < 0.05) beta- to alpha-cell
conversion in Ins1Cre/+;Rosa26-eYFP mice and glucagon expressing alpha-cells in
GluCreERT2;ROSA26-eYFP mice. These data indicate that islet benefits of prolonged
NPY1R activation, and especially restoration of beta-cell mass, are observed
irrespective of diabetes status, being linked to cell lineage alterations including
transdifferentiation of alpha- to beta-cells.
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Recent investigations have confirmed beneficial effects of
sustained activation of pancreatic beta-cell neuropeptide Y1
receptors (NPY1R’s) on the growth, survival and overall
secretory function of insulin-producing cells (1–5). In this
regard, enzymatically stable PYY(1–36) peptides from
phylogenetically ancient fish have been demonstrated to
function as long-acting, potent and specific NPY1R agonists
(4). Although the NPY1R is not believed to be expressed on
pancreatic alpha-cells, PYY is known to be locally secreted from
these alpha-cells (6), and positive effects of the piscine-derived
PYY(1-36) peptides on alpha-cell morphology and glucagon
secretion have also been noted (4). Since diabetes is a
metabolic disorder characterized by both aberrant alpha- and
beta-cell secretory function (7, 8), it suggests NPY1R modulation
may have extremely credible antidiabetic potential (9). Indeed,
the most efficacious piscine-derived PYY(1-36) sequence, namely
sea lamprey PYY(1-36) (SL-PYY(1-36)) (4), has already been
shown to combat beta-cell loss in diabetic rodents via
augmentation of beta-cell proliferation and a reduction in
apoptosis (4).
These positive islet effects are unlikely to account for the full
pancreatic architectural benefits of SL-PYY(1-36). As such,
although changes in beta-cell growth and survival were
significantly improved following sustained SL-PYY(1-36)
administration, relative changes were modest in quantitative
terms, with less obvious impact on alpha-cell turnover (4). In
relation to this, recent elegant cell lineage tracing studies have
highlighted the transitioning ability of mature islet alpha- and beta-
cells, leading to alterations in islet architecture, especially in
diabetes (10–13). Thus, despite their conflicting roles in the
control of blood glucose, alpha- and beta-cells share similar
transcriptomes (14, 15), and it seems plausible that SL-PYY(1-
36) might influence transdifferentiation of both cell types, to help
elicit the observed NPY1R-mediated improvements in pancreatic
islet morphology (4, 5, 16). Importantly in terms of clinical
relevance, islet cell transdifferentiation is not restricted to rodents
and has been evidenced in human beta-cells (17–20) and islet cells
from patients with diabetes (21). Therefore, the present study was
conducted using transgenic mice with alpha- and beta-cell lineage
tracing capabilities, to investigate the contribution of
transdifferentiation of alpha- and beta-cells to SL-PYY(1-36)-
induced improvements of pancreatic islet architecture in diabetes.
Fully characterized GluCreERT2;ROSA26-eYFP and Ins1Cre/+;
Rosa26-eYFP transgenic mouse models (22, 23) were used to
directly investigate the impact of sustained NPY1R signaling on
both alpha- to beta-, as well as beta- to alpha-cell,
transdifferentiation, respectively. It is generally considered that
islet cell transdifferentiation only occurs following severe
pancreatic insult, as experienced in diabetes (11). Thus, in the
current setting chemically induced beta-cell ablation was used
to provoke and study transdifferentiation of individual alpha-
and beta-cells in GluCreERT2;ROSA26-eYFP and Ins1Cre/+;Rosa26-
eYFP mice (10). Importantly, this method of diabetes induction
aligns well with previous investigations on the antidiabetic and
pancreatic architectural benefits of SL-PYY(1-36) treatment (4).Frontiers in Endocrinology | www.frontiersin.org 2Therefore, the impact of sub-chronic pharmacological
upregulation of NPY1R pathways in the two diabetic
transgenic rodent models was investigated, through 11-day
twice daily administration of SL-PYY(1-36). Taken together,
our datasets suggest that pancreatic islet architectural benefits
of prolonged NPY1R activation in diabetes are partly linked to
positive alteration of the transdifferentiation of both alpha- and
beta-cells.MATERIALS AND METHODS
Peptides
SL-PYY(1-36) was supplied by Synpeptide Ltd (Shanghai, China)
at greater than 95% purity and characterized in-house by HPLC
with MALDI-TOF, as described previously (24). Specificity of
SL-PYY(1-36) for NPY1R has previously been confirmed using
receptor knockout cell lines (4).
Generation of GluCreERT2;Rosa26-eYFP and
Ins1Cre/+;Rosa26-eYFP mice
Transgenic GluCreERT2;Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFP
C57BL/6 mice were bred in-house at the Biomedical and
Behavioural Research Unit (BBRU) at Ulster University, Coleraine.
Full details of the generation and characterization of mouse models
are provided by Campbell et al., 2020 (22) and Tanday et al., 2020a
(23), respectively. It is important to note thatGluCreERT2 and Ins1Cre/+
are not equivalent lineage tracers. As such, Ins1Cre/+ will come on as
soon as a cell makes Ins1, whereas GluCreERT2 will only label cells
producing glucagonwhenconcomitantly exposed to tamoxifen. PCR
genotyping for each colony was employed as previously described
(12, 22). GluCreERT2;Rosa26-eYFP animals were administered
tamoxifen (7 mg/mouse bw, i.p.), 2 days prior to the first STZ
injection, to induce expression of the alpha-cell fluorescent lineage
marker protein. All experiments were carried out under the UK
Animals (Scientific Procedures) Act 1986 & EU Directive 2010/
63EU. Animals were used at 14 weeks of age and weremaintained in
an environmentally controlled unit at 22 ± 2°C with a 12 h dark and
light cycle and given ad libitum access to standard rodent diet (10%
fat, 30% protein and 60% carbohydrate; Trouw Nutrition,
Northwich, UK) and drinking water.
Experimental Protocols
Multiple low dose streptozotocin (STZ) injection regimen (4 h fast,
50 mg/kg bw, i.p., in sodium citrate buffer, pH 4.5) was employed in
bothmouse models for 5 consecutive days to induce diabetes. Upon
biochemical confirmation of diabetes development, mice received
twice-daily (09:00 and 17:00 h) treatment with either saline vehicle
(0.9% (w/v) NaCl) or SL-PYY(1-36) (25 nmol/kg bw) for 11 days.
This dosing regimen was based on previous studies with SL-PYY(1-
36) and related peptides in STZ-diabetic mice (4, 5). Body weight,
blood glucose, cumulative food and fluid intake as well as
circulating glucose levels were assessed at regular intervals. At the
end of the treatment period, non-fasting and fasting plasma insulin,
as well as non-fasting plasma glucagon concentrations were
determined. At termination, pancreatic tissues were excised,February 2021 | Volume 12 | Article 633625
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pancreatic hormone content following acid/ethanol protein
extraction or fixed in 4% PFA for 48 h at 4°C for histological
analysis (4, 5). Despite using an identical approach to STZ
administration in both groups of transgenic mice, Ins1Cre/+;
Rosa26-eYFP mice, derived directly from breeding pairs obtained
from Jackson Laboratories (Bar Harbor, Maine, USA), developed a
more severe diabetes phenotype. This most likely reflects differences
in background genome compared to the GluCreERT2;Rosa26-eYFP
mouse model, which affected STZ susceptibility (25, 26).
Immunohistochemistry
Fixed tissues were processed and embedded in paraffin wax blocks
using an automated tissue processor (Leica TP1020, Leica
Microsystems), and 5 mm sections cut on a microtome
(Shandon Finesse 325, Thermo Scientific), and sections selected
at intervals of every 10 sections. Slides were dewaxed by
immersion in xylene and rehydrated through a series of ethanol
solutions of reducing concentration (100%–50%). Heat-mediated
antigen retrieval was then carried out in citrate buffer. Sections
were blocked in 4% BSA solution before 4°C overnight incubation
with appropriate primary antibodies (Table 1), Slides were then
rinsed in PBS and incubated for 45 min at 37°C with appropriate
Alexa Fluor secondary antibodies (Table 1). Slides were finally
incubated with DAPI for 15 min at 37°C, and then mounted for
imaging using a fluorescent microscope (Olympus model BX51)
fitted with DAPI (350 nm) FITC (488 nm) and TRITC (594 nm)
filters and a DP70 camera adapter system (27).
Image Analysis
CellF imaging software (Olympus Soft Imaging Solutions) was
used to analyze islet architectural parameters. Positive islet GFP
staining was used to track lineage of alpha-cells in GluCreERT2;
Rosa26-eYFP mice and beta-cells in Ins1Cre/+;Rosa26-eYFP
transgenic mice. For transdifferentiation, cells expressing GFP
without insulin or glucagon were termed insulin-ve/GFP+ve or
glucagon-ve/GFP+ve, respectively. Cells co-expressing GFP with
insulin or glucagon were termed insulin+ve/GFP+ve or
glucagon+ve/GFP+ve cells, respectively. The proportion of
insulin+ve/GFP+ve or glucagon+ve/GFP+ve cells was expressed as
a percentage of the total number of GFP+ve cells analyzed. Every
cell that was positive for ether insulin, glucagon and/or GFP wasFrontiers in Endocrinology | www.frontiersin.org 3counted. All cell counts were determined in a blinded manner
with >100 islets analyzed per treatment group.
Biochemical Analyses
Blood sampleswere collected from the cut tail vein of animals. Blood
glucose was measured using a portable Ascencia Contour blood
glucose meter (Bayer Healthcare, Newbury, Berkshire, UK). For
plasma insulin and glucagon, bloodwas collected in chilledfluoride/
heparin coated microcentrifuge tubes (Sarstedt, Numbrecht,
Germany) and centrifuged using a Beckman micro-centrifuge
(Beckman Instruments, Galway, Ireland) for 10 min at 12,000
rpm. Plasma was extracted and stored at −20°C, until required for
analysis. For hormone content, snap frozen pancreatic tissues were
homogenized in acid/ethanol (75% (v/v) ethanol, distilledwater and
1.5% (v/v) 12 M HCl) and protein extracted in a pH neutral TRIS
buffer. Protein content was determined using Bradford reagent
(Sigma-Aldrich). Plasma and pancreatic insulin content were
determined by an in-house insulin RIA (28), while plasma and
pancreatic glucagon content were assessed by a commercially
available ELISA kit (Glucagon chemiluminescent assay, EZGLU-
30K, Millipore) following the manufacturer’s guidelines.
Statistics
Data were analyzed using GraphPad PRISM 5.0, with data
presented as mean ± SEM. Comparative analyses between control
and experimental groups of GluCreERT2;Rosa26-eYFP or Ins1Cre/+;
Rosa26-eYFPmice were carried out using Student’s unpaired t-test,
one-way ANOVA with a Bonferroni post hoc test or a two-way
repeated measures ANOVA with a Bonferroni post hoc test, as
appropriate. Results were deemed significant once p < 0.05.RESULTS
Effects of SL-PYY(1-36) on Body Weight
and Cumulative Food and Fluid Intake in
STZ-Diabetic GluCreERT2;Rosa26-eYFP and
Ins1Cre/+;Rosa26-eYFP Mice
STZ induced a decline in body weight in GluCreERT2;Rosa26-eYFP
and Ins1Cre/+;Rosa26-eYFP mice (Figures 1A, B). Twice-daily
SL-PYY(1-36) administration was unable to reverse this effect inTABLE 1 | Target, host and source of primary and secondary antibodies employed for immunofluorescent islet histology and immunocytochemistry studies.
Primary antibodies
Target Host Dilution Source
Insulin Mouse 1:500 Abcam, ab6995
Glucagon Guinea pig 1:200 Raised in-house, PCA2/4
GFP Goat 1:400 Abcam, ab5450
Secondary antibodies
Target Host Reactivity Dilution Fluorescent dye and source
IgG Goat Mouse 1:400 Alexa Fluor® 594, Invitrogen, UK
IgG Goat Guinea pig 1:400 Alexa Fluor® 594, Invitrogen, UK
IgG Goat Guinea pig 1:400 Alexa Fluor® 488, Invitrogen, UK
IgG Donkey Goat 1:400 Alexa Fluor® 488, Invitrogen, UKFebruary 2021 | Volume 12 | Article 633625





FIGURE 1 | Effects of twice-daily administration of sea lamprey PYY [SL-PYY (1-36)] on (A, B) body weight, (C, D) % body weight change as well as cumulative
(E, F) food and (G, H) fluid intake in streptozotocin (STZ)-diabetic GluCreERT2;Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFP mice. Parameters were measured prior to,
and 11 days during, twice daily treatment with saline vehicle or SL-PYY(1-36) (25 nmol/kg bw) in STZ-diabetic GluCreERT2;Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFP
mice. Values are mean ± SEM (n=6). Dp < 0.05, DDp < 0.01, DDDp < 0.001 compared to appropriate non-diabetic control. *p < 0.05, **p < 0.01, ***p < 0.001
compared to appropriate STZ-diabetic control.Frontiers in Endocrinology | www.frontiersin.org February 2021 | Volume 12 | Article 6336254
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body weight change being remarkably similar to respective STZ-
diabetic control mice (Figures 1C, D). There were differences
between the mouse models in terms of food and fluid intake, with
elevations (p < 0.001) of both parameters being only transient in
nature in GluCreERT2;Rosa26-eYFP STZ-diabetic mice and totally
absent from day 4 onwards (Figures 1E, G). In Ins1Cre/+;Rosa26-
eYFP mice, STZ elevated (p < 0.01 – p < 0.001) food and fluid
intake from day 4 onwards (Figures 1F, H), with SL-PYY(1-36)
significantly (p < 0.05 – p < 0.001) reducing increased fluid
consumption on days 8, 10 and 11 (Figure 1H).Effects of SL-PYY(1-36) on Circulating
Glucose, Insulin and Glucagon, as Well as
Pancreatic Insulin and Glucagon Content,
in STZ-Diabetic GluCreERT2;Rosa26-eYFP
and Ins1Cre/+;Rosa26-eYFP Mice
Non-fasted circulating blood glucose levels were significantly (p <
0.05 – p < 0.001) elevated when compared to respective saline
controls in STZ-diabetic GluCreERT2;Rosa26-eYFP and Ins1Cre/+;
Rosa26-eYFP mice (Figures 2A, B). SL-PYY(1-36) treatment
reduced (p < 0.05 - p < 0.001) glucose concentrations in both
mouse models, specifically, reversing and substantially delaying
overt hyperglycaemia in GluCreERT2;Rosa26-eYFP and Ins1Cre/+;Frontiers in Endocrinology | www.frontiersin.org 5Rosa26-eYFP mice, respectively (Figures 2A, B). Indeed,
terminal blood glucose levels following a 16 hour fast were
similar to non-diabetic controls in SL-PYY(1-36) treated
GluCreERT2;Rosa26-eYFP STZ mice, but still significantly (p <
0.001) elevated in Ins1Cre/+;Rosa26-eYFP treated STZ mice
(Figure 2C). In agreement, corresponding fasted and non-
fasted plasma insulin concentrations in SL-PYY(1-36) treated
GluCreERT2;Rosa26-eYFP animals were elevated (p < 0.001 and
p < 0.05; respectively) compared to STZ-diabetic controls, and
not different from non-diabetic control mice (Figures 2D, E).
Insulin concentrations were also significantly reduced (p <
0.001) in all STZ-diabetic Ins1Cre/+;Rosa26-eYFP mice (Figures
2D, E). Interestingly, fasted insulin concentrations, but not non-
fasted, were increased (p < 0.05) in SL-PYY(1-36) treated
Ins1Cre/+;Rosa26-eYFP mice when compared to STZ-diabetic
controls (Figures 2D, E), but still reduced (p < 0.001) in
comparison to lean control mice (Figure 2E). Non-fasted
plasma glucagon levels were not different in any of the
GluCreERT2;Rosa26-eYFP mice, but elevated (p < 0.05 and p <
0.01) when compared to non-diabetic controls in all STZ Ins1Cre/
+;Rosa26-eYFPmice (Figure 2F). Pancreatic insulin content was
dramatically (p < 0.001) increased in SL-PYY(1-36) treated
GluCreERT2;Rosa26-eYFP mice when compared to STZ-diabetic
controls, with pancreatic glucagon elevated (p < 0.01 and p < 0.001)




FIGURE 2 | Effects of twice-daily administration of sea lamprey PYY [SL-PYY (1-36)] on blood glucose as well as plasma and pancreatic insulin and glucagon
concentrations in streptozotocin (STZ)-diabetic GluCreERT2;Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFP mice. Blood glucose was measured at regular intervals during
11 days twice daily treatment with saline vehicle or SL-PYY(1-36) (25 nmol/kg bw) in STZ-diabetic (A) GluCreERT2;Rosa26-eYFP or (B) Ins1Cre/+;Rosa26-eYFP mice.
Terminal analysis included measurement of overnight fasted (C) glucose and (E) insulin, non-fasted (D) insulin, and (F) glucagon as well pancreatic (G) insulin and
(H) glucagon. Values are mean ± SEM (n=6). Dp < 0.05, DDp <.01, DDDp < 0.001 compared to appropriate non-diabetic control. *p < 0.05, **p < 0.01, ***p < 0.001
compared to appropriate STZ control.February 2021 | Volume 12 | Article 633625
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when compared to STZ-diabetic and non-diabetic control Ins1Cre/+;
Rosa26-eYFP mice (Figure 2H), with pancreatic insulin content
increased (p < 0.05) compared to STZ-diabetic controls but still
reduced (p < 0.001) in comparison to lean control mice
(Figure 2G).
Effects of SL-PYY(1-36) on Pancreatic Islet
Morphology in STZ-Diabetic GluCreERT2;
Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFP
Mice
The detrimental effects of multiple low dose STZ administration on
pancreatic islet morphology in both GluCreERT2;Rosa26-eYFP and
Ins1Cre/+;Rosa26-eYFP mice is clear from the representative islet
images depicted in Figures 3A–F, and largely consistent between
models apart from substantially greater beta-cell loss in Ins1Cre/+;
Rosa26-eYFPmice. Specifically, STZ induced significant (p < 0.001)
reductions in average islet and beta-cell areas, with increased (p <
0.05 to p < 0.001) alpha-cell area (Figures 3G–I) in both transgenic
mouse models. SL-PYY(1-36) had no impact on STZ-induced
elevations of pancreatic alpha-cell area (Figure 3I). In contrast, SL-
PYY(1-36) treatment substantially (p < 0.001) increased islet and
beta-cell areas in both GluCreERT2;Rosa26-eYFP and Ins1Cre/+;
Rosa26-eYFP mice (Figures 3G, H). Indeed, these parameters
were similar to non-diabetic control mice in the GluCreERT2;
Rosa26-eYFP model (Figures 3G, H). Interestingly, SL-PYY(1-
36)-induced changes of islet cell areas in both models were
accompanied by architectural modifications that included a
reduced penetration of alpha-cells into the central portion of theFrontiers in Endocrinology | www.frontiersin.org 6islet, especially in GluCreERT2;Rosa26-eYFP animals (Figure 3J) and
increased (p < 0.05) numbers of islets per mm2 tissue (Figure 3K).
Effects of SL-PYY(1-36) on Islet Cell
Lineage in STZ-Diabetic GluCreERT2;
Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFP
Mice
In GluCreERT2;Rosa26-eYFP mice, STZ resulted in a reduction (p <
0.001) in the number of cells co-expressing insulin and GFP
(insulin+ve/GFP+ve), an effect that was fully reversed (p < 0.01) by
twice daily SL-PYY(1-36) treatment (Figure 4A). Representative
images of islets from GluCreERT2;Rosa26-eYFP and Ins1Cre/+;
Rosa26-eYFP mice co-stained for GFP and insulin or glucagon
are shown in Figures 5B–D, F–H. Representative images of insulin
and GFP stained islets from each group of mice are provided in
Figures 4B–D. Interestingly, while STZ did not alter the number of
islet cells co-expressing glucagon and GFP (glucagon+ve/GFP+ve) in
GluCreERT2;Rosa26-eYFP mice, SL-PYY(1-36) decreased the
number of these co-expressing cells when compared to both
STZ-diabetic (p < 0.001) and non-diabetic (p < 0.05) control
mice (Figures 4E). Representative images of glucagon and GFP
stained islets are depicted in Figures 4F–H. Similar, albeit in mice
with non-inducible GFP expression, islet cell lineage investigations
were conducted in Ins1Cre/+;Rosa26-eYFP mice, revealing
comparable beneficial effects of SL-PYY(1-36) despite differences
in the diabetes phenotype of the two transgenic models (Figure 5).
As such, STZ treatment in this mouse model resulted in increased
(p < 0.001) percentages of insulin negative, GFP positive (insulin-ve/




FIGURE 3 | Effects of twice-daily administration of sea lamprey PYY [SL-PYY (1-36)] on pancreatic islet morphology in streptozotocin (STZ)-diabetic GluCreERT2;
Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFP mice. Parameters were assessed after 11 days treatment with saline vehicle or SL-PYY(1-36) (25 nmol/kg bw).
(A–F) Representative images (40×) from each treatment group for (A–C) GluCreERT2;Rosa26-eYFP and (D–F) Ins1Cre/+;Rosa26-eYFP mice are depicted.
Average (D) islet, (H) beta-, and (I) alpha-cell areas, as well as (J) the proportion of islets possessing centrally located alpha-cells and (K) number of islets per
mm2. Values are means ± SEM of 6 mice per group, with approximately 100 islets being analyzed per group. Dp < 0.05, DDp < 0.01, DDDp < 0.001 compared
to appropriate non-diabetic control. *p < 0.05, ***p < 0.001 compared to appropriate STZ control.February 2021 | Volume 12 | Article 633625
Lafferty et al. NPYR1 and Islet Cell Transdifferentiationdaily SL-PYY(1-36) treatment significantly (p < 0.01) reduced
percentages of insulin-ve/GFP+ve islet cells (Figure 5A) and
returned percentages of glucagon+ve/GFP+ve cells similar to those
observed in non-diabetic control mice (Figures 5E). Representative
images of islets fromGluCreERT2;Rosa26-eYFP and Ins1Cre/+;Rosa26-
eYFP mice co-stained for GFP and insulin or glucagon are shown
in Figures 5B–D, F–H.Frontiers in Endocrinology | www.frontiersin.org 7DISCUSSION
As expected, multiple low dose STZ administration resulted in
characteristic pancreatic islet beta-cell destruction, acute insulin
deficiency and elevations of blood glucose in both GluCreERT2;
Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFP transgenic mice.
Interestingly, appreciable differences were apparent between theseA B D
E F G H
C
FIGURE 4 | Effects of twice-daily administration of sea lamprey PYY [SL-PYY (1-36)] on islet cell lineage in streptozotocin (STZ)-diabetic GluCreERT2;Rosa26-eYFP
mice. Parameters were assessed after 11 days treatment with saline vehicle or SL-PYY(1-36) (25 nmol/kg bw). Quantification of (A) glucagon+ve/GFP+ve and
(E) insulin+ve/GFP+ve islet stained cells. Representative images (40×) of islets showing (B–D) insulin (red) or (F–H) glucagon (red) as well as GFP (green) and
DAPI (blue) immunoreactivity from each group of mice; scale bar 50 mm. Values are means ± SEM of six mice per group, with approximately 100 islets being
analyzed per group. Dp < 0.05, DDDp < 0.001 compared to appropriate non-diabetic control. **p < 0.01, ***p < 0.001 compared to appropriate STZ control.A B D
E F G H
C
FIGURE 5 | Effects of twice-daily administration of sea lamprey PYY [SL-PYY(1–36)] on islet cell lineage in streptozotocin (STZ)-diabetic Ins1Cre/+;Rosa26-eYFP
mice. Parameters were assessed after 11 days treatment with saline vehicle or SL-PYY(1–36) (25 nmol/kg bw). Quantification of (A) insulin-ve/GFP+ve and
(E) glucagon+ve/GFP+ve islet stained cells. Representative images (40×) of islets showing (B–D) insulin (red) or (F–H) glucagon (red) as well as GFP (green) and
DAPI (blue) immunoreactivity from each group of mice; scale bar 50 mm. Values are means ± SEM of six mice per group, with approximately 100 islets being
analyzed per group. DDDp < 0.001 compared to appropriate non-diabetic control. *p < 0.05, **p < 0.01 compared to appropriate STZ control.February 2021 | Volume 12 | Article 633625
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weight, food and fluid intake as well as alpha-cell derived circulating
glucagon and degree of hyperglycaemia, that indicated a more
severe diabetic phenotype in Ins1Cre/+;Rosa26-eYFP mice.
Although unlikely given the mechanism of action of STZ (29),
presence of the transgene within beta-cells of Ins1Cre/+;Rosa26-eYFP
mice could contribute to the difference in susceptibility to the toxin.
However, studies in GluCreERT2;ROSA26-eYFP mice confirm that
activation of the Cre recombinase enzyme does not affect normal
islet cell processes (22), and although unlikely, production of
fluorescent GFP protein within beta cells of Ins1Cre/+;Rosa26-eYFP
mice could increase metabolic demand leaving cells more
susceptible to STZ. GluCreERT2;Rosa26-eYFP mice, unlike Ins1Cre/+;
Rosa26-eYFP, also require a single, low-dose, tamoxifen injection to
induce Cre-lox recombination, raising the possibility that estrogen
receptor antagonism might curb some detrimental effects of STZ,
but this appears only to occur during sub-chronic dosing regimen
(30). Indeed, the use of tamoxifen-dependent Cre recombinase
induction is a commonly employed tool to successfully study
gene function with minimal adverse effects. However, we
recognize that an additional group of control GluCreERT2;Rosa26-
eYFP mice would have been useful to confirm lack of effect of the
single dose of tamoxifen on diabetic phenotype. A more likely
explanation relates to variations in STZ susceptibility between (25),
and even within (26), strains of mice, comparable to the established
gender variations of STZ effects in rodents (31). However, given
both transgenic mouse models displayed clear STZ-induced beta-
cell ablation, with distinct diabetes-induced alterations in islet cell
transitioning (23, 32), they represent valid tools to assess the impact
of sustained NPY1R agonism on alpha- to beta- and beta- to alpha-
cell transdifferentiation. Moreover, the difference in presenting
diabetic phenotype of GluCreERT2;Rosa26-eYFP and Ins1Cre/+;
Rosa26-eYFP mice allows for differentiation between direct
positive effects of SL-PYY(1-36) on islet cell transdifferentiation,
as opposed to indirect benefits related to improved glycaemic
control and metabolic status. However, because GluCreERT2 and
Ins1Cre/+ are not equivalent lineage tracers, labeling islet cells either
during tamoxifen exposure or from the moment of Ins1 expression,
respectively, direct quantitative comparisons of islet cell changes
between the models should be avoided.
In keeping with earlier observations (4), SL-PYY(1-36)
increased beta-cell area, plasma and pancreatic insulin in both
GluCreERT2;Rosa26-eYFP and Ins1Cre/+;Rosa26-eYFPmice, as well as
reversing the characteristic infiltration of glucagon positively
stained central alpha-like cells (4, 5). Beta-cell benefits are
undoubtedly linked, in part, to increased proliferation and
reduced beta-cell apoptosis, as documented previously with
sustained NPY1R activation in diabetic mouse models (1, 4, 5).
Interestingly, previous studies in insulin-deficient mice also
demonstrated reductions in alpha-cell area following SL-PYY(1-
36) treatment, which coupled with increased beta-cell mass,
resulted in no obvious change in overall pancreatic islet area (4,
5). In the current setting, islet area increased with 11-day SL-PYY
(1-36) treatment in both diabetic transgenic models, as a result of
elevations in alpha- and beta-cell areas. We assume that the slightly
different scenario compared to our previous study (4) is related toFrontiers in Endocrinology | www.frontiersin.org 8differences in the strain of mice employed and associated
physiological responses to STZ (26), as well as duration of SL-
PYY(1-36) treatment. Nonetheless, observed metabolic and islet
benefits reaffirm the recognized beta-cell pro-survival effects of
NPYR1 signaling (16). This established benefit, coupled with
evidence of beta-cell loss following selective KO of PYY
expressing cells (1), as well as expansion of PYY expressing
alpha-cell like islet cell populations during regeneration of the
adult pancreas (33), indicate the importance of NPY receptor
signaling for positive islet cell adaptations in response to
metabolic stress. Furthermore, upregulation of NPY receptor
activation has also been linked to the improved insulin secretion
and resolution of diabetes following bariatric surgery (34–36).
In terms of islet cell lineage tracing, studies in Ins1Cre/+;Rosa26-
eYFP mice revealed that STZ induced notable increases in the
number of pancreatic beta-cells losing their identity, as well as
mature beta-cells transitioning to glucagon positive alpha-like cells
(23). Interestingly, in GluCreERT2;Rosa26-eYFP mice a seemingly
high intrinsic transition of glucagon positive alpha-cells to insulin
positive beta-cells was decreased by STZ intervention. Triple
staining of GFP, glucagon and insulin would have been useful to
provide additional insight on these islet cell lineage processes,
especially in GluCreERT2;Rosa26-eYFP mice, but was not possible
due to methodological constraints. Furthermore, STZ susceptibility
of cells transitioning from/to beta-cells and the relevance of
established cytoprotective effects of SL-PYY(1-36) in such cell
populations are unknown. However, when taken together, the
data suggest that a likely source of the additional positively
stained glucagon cells in both diabetic models in the present
study is linked to transdifferentiation of beta-cells toward alpha-
cells and possible lack of alpha-cell dedifferentiation, although the
latter point requires further investigation. Most importantly, SL-
PYY(1-36) treatment appeared to be able to fully, or partially,
counter each of these STZ-induced detrimental islet cell
transdifferentiation events. Intriguingly, despite increased alpha-
cell area, pancreatic glucagon content was decreased by SL-PYY
(1-36) treatment in both mouse models. This might suggest that a
significant number of alpha-cells were currently in the process of
transition, probably toward a more beta-cell like phenotype, and
therefore have reduced glucagon content. In full agreement, SL-PYY
(1-36) reduced the percentage of glucagon+ve/GFP+ve cells in
GluCreERT2;Rosa26-eYFP mice, and augmented alpha- to beta-cell
transdifferentiation. The location on different mouse islet cells of
NPY1R, which we detected previously to be expressed at relatively
low levels by alpha-, beta- and delta-cells and the role of endogenous
PYY, expressed in adult mouse alpha- and delta-cells (37), will need
to be determined in the future. In terms of alpha-cell secretion, non-
fasted circulating glucagon concentrations were unaltered by SL-
PYY(1-36), however it is envisaged that any effect on glucagon
would be more apparent under fasting conditions, which
unfortunately were not assessed in the current study.
Unlike Ins1Cre/+;Rosa26-eYFP mice, the GluCreERT2;Rosa26-eYFP
transgenic model exhibited an almost complete restoration
of normoglycaemia, suggesting that exogenous peptide
administration can directly influence islet cell transdifferentiation.
As such, improvements in glycaemic status have been shown toFebruary 2021 | Volume 12 | Article 633625
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dependent mechanisms still need to be investigated, and although
beyond the scope of the current study, consideration of levels of
specific alpha- and beta-cell transcription factors such as aristaless-
related homeobox (Arx) (39), paired box gene 4 (Pax4) (40),
pancreatic and duodenal homeobox 1 (Pdx-1) or forkhead box
O1 (FOXO1) (41) would be interesting. Indeed, in the absence of
such additional investigations, some constraint is required in terms
of interpretation of the full impact of SL-PYY(1-36) on
transdifferentiation of alpha- to beta-cells. Findings should also be
interpreted in relation to the decrease in islet PYY expression
observed following STZ-induced insulin deficiency in rodents (1,
16), although islet PYY levels were not directly assessed in the
current setting. In addition, observations of increased numbers of
individual islets following SL-PYY(1-36) treatment might suggest
islet neogenesis is involved in beneficial NPYR1 mediated islet
adaptations, but this would also require further, more detailed study.
Indeed, an established role for PYY during rapid islet cell
development and replication within the embryo makes this
scenario plausible and worthy of investigation (42). In this regard,
it may be interesting to assess the impact of SL-PYY(1-36) on islet
cell lineage under normal physiological conditions.CONCLUSION
The present study demonstrates that sustained NPYR1 activation by
SL-PYY(1-36) rescued beta-cell loss and augmented beta-cell
function in chemically induced insulin-deficient diabetes, leading
to significantly enhanced overall metabolic control. As well as
increased proliferation and reduced apoptosis of beta-cells (3–5,
16), SL-PYY(1-36) also appeared to positively influence the
transitioning of both islet alpha- and beta-cells. This newly
discovered, beneficial islet cell lineage effect emphasizes the
potential of stable long-acting NPYR1 agonists to promote
prevailing, disease-modifying benefits in diabetes, linked to
possible alteration of alpha cell function and transdifferentiation
of alpha- to beta-cells.Frontiers in Endocrinology | www.frontiersin.org 9DATA AVAILABILITY STATEMENT
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